Login to Your Account

NicOx Shares Rise on Phase IIb Glaucoma Data, $10M Milestone

By Cormac Sheridan
Staff Writer

Wednesday, March 14, 2012
Shares in NicOx SA rose more than 44 percent Tuesday on news that its glaucoma drug BOL-303259-X, which is partnered with Bausch & Lomb Inc., met the primary endpoint in a Phase IIb trial and will progress to a global Phase III development program within a year.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription